ONCOSEC MEDICAL Inc Quarterly Research and Development Expense in USD from Q3 2015 to Q4 2022

Taxonomy & unit
us-gaap: USD
Description
The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.
Summary
ONCOSEC MEDICAL Inc quarterly/annual Research and Development Expense history and growth rate from Q3 2015 to Q4 2022.
  • ONCOSEC MEDICAL Inc Research and Development Expense for the quarter ending January 31, 2023 was $4.65M, a 31.8% decline year-over-year.
  • ONCOSEC MEDICAL Inc Research and Development Expense for the twelve months ending January 31, 2023 was $21.8M, a 24.5% decline year-over-year.
  • ONCOSEC MEDICAL Inc annual Research and Development Expense for 2022 was $25.8M, a 24.3% decline from 2021.
  • ONCOSEC MEDICAL Inc annual Research and Development Expense for 2021 was $34.1M, a 35.9% increase from 2020.
  • ONCOSEC MEDICAL Inc annual Research and Development Expense for 2020 was $25.1M, a 36.1% increase from 2019.
Research and Development Expense, Trailing 12 Months (USD)
Research and Development Expense, Quarterly (USD)
Research and Development Expense, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q4 2022 $21.8M $4.65M -$2.17M -31.8% Nov 1, 2022 Jan 31, 2023 10-Q 2023-03-14
Q3 2022 $23.9M $4.77M -$1.88M -28.3% Aug 1, 2022 Oct 31, 2022 10-Q 2022-12-15
Q2 2022 $25.8M $5.32M -$2.47M -31.7% May 1, 2022 Jul 31, 2022 10-K 2022-10-31
Q1 2022 $28.3M $7.03M -$559K -7.37% Feb 1, 2022 Apr 30, 2022 10-Q 2022-06-14
Q4 2021 $28.9M $6.83M -$2.09M -23.4% Nov 1, 2021 Jan 31, 2022 10-Q 2023-03-14
Q3 2021 $30.9M $6.65M -$3.15M -32.2% Aug 1, 2021 Oct 31, 2021 10-Q 2022-12-15
Q2 2021 $34.1M $7.79M +$275K +3.66% May 1, 2021 Jul 31, 2021 10-K 2022-10-31
Q1 2021 $33.8M $7.59M +$1.49M +24.4% Feb 1, 2021 Apr 30, 2021 10-Q 2022-06-14
Q4 2020 $32.3M $8.92M +$2.86M +47.2% Nov 1, 2020 Jan 31, 2021 10-Q 2022-03-15
Q3 2020 $29.5M $9.8M +$4.38M +80.8% Aug 1, 2020 Oct 31, 2020 10-Q 2021-12-15
Q2 2020 $25.1M $7.52M +$2.78M +58.7% May 1, 2020 Jul 31, 2020 10-K 2021-10-29
Q1 2020 $22.3M $6.1M +$1.88M +44.6% Feb 1, 2020 Apr 30, 2020 10-Q 2021-06-11
Q4 2019 $20.4M $6.06M +$1.31M +27.6% Nov 1, 2019 Jan 31, 2020 10-Q 2021-03-15
Q3 2019 $19.1M $5.42M +$681K +14.4% Aug 1, 2019 Oct 31, 2019 10-Q 2020-12-11
Q2 2019 $18.4M $4.74M May 1, 2019 Jul 31, 2019 10-K 2020-10-28
Q1 2019 $4.22M Feb 1, 2019 Apr 30, 2019 10-Q 2020-06-15
Q4 2018 $4.75M Nov 1, 2018 Jan 31, 2019 10-Q 2020-03-16
Q3 2018 $4.74M Aug 1, 2018 Oct 31, 2018 10-Q 2019-12-13
Q2 2017 $12M $3.31M -$278K -7.73% May 1, 2017 Jul 31, 2017 10-K 2017-10-25
Q1 2017 $12.2M $2.66M -$721K -21.3% Feb 1, 2017 Apr 30, 2017 10-K 2017-10-25
Q4 2016 $13M $2.88M -$1.23M -29.9% Nov 1, 2016 Jan 31, 2017 10-K 2017-10-25
Q3 2016 $14.2M $3.1M -$560K -15.3% Aug 1, 2016 Oct 31, 2016 10-K 2017-10-25
Q2 2016 $14.7M $3.59M May 1, 2016 Jul 31, 2016 10-K 2017-10-25
Q1 2016 $3.38M Feb 1, 2016 Apr 30, 2016 10-K 2017-10-25
Q4 2015 $4.11M Nov 1, 2015 Jan 31, 2016 10-K 2017-10-25
Q3 2015 $3.66M Aug 1, 2015 Oct 31, 2015 10-K 2017-10-25
* An asterisk sign (*) next to the value indicates that the value is likely invalid.